Welcome to our dedicated page for Cidara Theraptcs SEC filings (Ticker: CDTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cidara Therapeutics, Inc. (CDTX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a former Nasdaq-listed biotechnology issuer. These documents include current reports on Form 8-K, financing-related filings, and other materials that describe Cidara’s clinical development plans, capital structure changes, government agreements, and its acquisition by Merck.
For investors and researchers analyzing Cidara’s business, the company’s 8-K filings are especially important. They detail key events such as the Agreement and Plan of Merger with Merck Sharp & Dohme LLC and a Merck subsidiary, the terms of the cash tender offer for all outstanding shares of common and Series A preferred stock, and the planned merger that will make Cidara a wholly owned subsidiary of Merck. These filings also outline conditions to closing, tender offer mechanics, termination fees, and other transaction terms.
Other 8-K reports describe Cidara’s clinical and regulatory progress with CD388. For example, filings explain updates to the planned Phase 3 registrational trial following an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), including expansion of the ANCHOR study population and the intention to seek biologics license application (BLA) approval based on a single Phase 3 study. Additional filings summarize positive topline results from the Phase 2b NAVIGATE trial and provide context on safety and prevention efficacy data.
Cidara’s filings also cover its Award/Contract with the Biomedical Advanced Research and Development Authority (BARDA) to support expanded manufacturing and clinical development of CD388, including base-period funding for onshoring manufacturing to the United States and potential option funding for further studies. Capital markets transactions, such as underwritten public offerings of common stock and suspension of an at-the-market (ATM) prospectus, are documented in 8-Ks that describe underwriting agreements, share issuance, and related legal opinions.
On Stock Titan, these SEC filings are updated from EDGAR and can be paired with AI-powered summaries that highlight the main points of each document. Users can quickly see what each 8-K, registration-related filing, or other report means for Cidara’s clinical programs, financing, and merger process. While Cidara’s common stock is expected to cease trading on the Nasdaq Global Market following completion of its merger with Merck, its historical filings remain a key resource for understanding the evolution of CD388, the Cloudbreak platform, and the corporate steps leading to the acquisition.
Venrock group reports a 3.2% passive stake in Cidara Therapeutics (CDTX) held collectively as of June 30, 2025. The filing lists 639,088 shares beneficially owned across Venrock entities: 134,554 shares held by Venrock Healthcare Capital Partners III, L.P.; 13,456 by VHCP Co-Investment Holdings III, LLC; and 491,078 by Venrock Healthcare Capital Partners EG, L.P. All reporting entities are Delaware-organized and report shared voting and dispositive power over the 639,088 shares and no sole voting or dispositive power. The percentage is calculated using 20,163,696 shares outstanding per the issuer prospectus supplement dated June 24, 2025. Signatures and powers of attorney are included by reference.
Cidara Therapeutics, Inc. (CDTX) received a Schedule 13G/A reporting that Point72-affiliated entities and Steven A. Cohen beneficially own 1,527,930 shares of common stock, representing 7.6% of the outstanding class as of June 30, 2025. The filing states those shares are held for investment by Point72 Associates and that Point72 Asset Management and Point72 Capital Advisors maintain shared voting and dispositive power over the shares; none of the reporting persons claim sole voting or dispositive power. The reporting address is 72 Cummings Point Road, Stamford, CT.
Canaan XII L.P. and Canaan Partners XII LLC filed Amendment No. 1 to Schedule 13G reporting that, as of June 30, 2025, neither reporting person beneficially owns any shares of Cidara Therapeutics, Inc. common stock (CUSIP 171757206). The filing lists each filer’s jurisdiction of organization and principal business address and states the holders have 0 sole or shared voting and dispositive power, representing 0.0% of the class.
Cidara Therapeutics' Schedule 13G/A discloses that Vivo Opportunity Fund Holdings, L.P. (and its general partner Vivo Opportunity, LLC) beneficially owns 1,175,796 shares of Cidara common stock, representing 4.6% of the outstanding class. Vivo Opportunity Cayman Fund, L.P. (and its general partner Vivo Opportunity Cayman, LLC) beneficially owns 135,629 shares, representing 0.5% of the class. Each reporting person reports sole voting and sole dispositive power over the shares they hold of record through the funds. The filing states the holdings were not acquired to change or influence control of the issuer and ties beneficial ownership to the funds and their general partners as disclosed in the issuer's public filings.
Adage Capital Management and two principals report a passive 4.97% stake in Cidara Therapeutics (CDTX), holding 1,100,000 shares in shared voting and dispositive power. The filings identify Adage Capital Management, L.P., Robert Atchinson and Phillip Gross as the reporting persons and state the position is held in the ordinary course of business and not to influence control. The percentage is calculated on a pro forma share count of 22,117,550 shares, which combines 12,969,823 outstanding shares as of May 5, 2025 and 9,147,727 shares issued under a June 25, 2025 prospectus after full exercise of the over-allotment.
The report shows 0 sole voting/dispositive power and 1,100,000 shares of shared voting/dispositive power, placing the holding under the 5% reporting threshold for greater-than-5% ownership.
RA Capital Management, its principals Peter Kolchinsky and Rajeev Shah, and RA Capital Healthcare Fund report beneficial ownership of 3,365,523 shares of Cidara Therapeutics common stock, representing 13.3% of 25,358,051 shares outstanding. The Fund also holds Series A preferred stock convertible into up to 6,296,920 common shares and pre-funded warrants exercisable for up to 1,286,786 common shares, but conversion and exercise are limited by contractual Beneficial Ownership Blockers that prevent the Fund from owning more than 9.99% of the common stock and currently prohibit conversion or exercise.
RA Capital is the investment adviser with sole power to vote and dispose of the Fund’s reported securities, and the Fund has delegated those powers and disclaims beneficial ownership for Section 13(d) purposes. No transactions have been reported since the prior amendment; the reported percentage reflects an increase in the issuer’s outstanding shares.
FAQ
What is the current stock price of Cidara Theraptcs (CDTX)?
What is the market cap of Cidara Theraptcs (CDTX)?
